Press Releases Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 08:29:45 12/06/2025 pm IST			5-day change	1st Jan Change
1,484.00 ^DKK	-0.03%		+2.80%	-0.44%

09/06	Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM
09/06	AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	MT

Press Releases

Transactions in Connection with Share Buy-back Program	10/06	GL
Genmab A/S : Rina-S Update at ASCO 2025	03/06	PU
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	03/06	BU
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	03/06	GL
Transactions in Connection with Share Buy-back Program	02/06	GL
Genmab A/S - Transactions in Connection with Share Buy-back Program	27/05	AQ
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference	27/05	GL
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference	27/05	AQ
Transactions in Connection with Share Buy-back Program	26/05	GL
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	BU
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	GL
Genmab A/S : Articles of association dated May 20, 2025 – English	21/05	PU
Genmab A/S : has published its Articles of Association	21/05	PU
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference	21/05	GL
Capital Increase in Genmab as a Result of Employee Warrant Exercise	20/05	GL
Transactions in Connection with Share Buy-back Program	19/05	GL
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress	14/05	BU
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress	14/05	GL
Transactions in Connection with Share Buy-back Program	12/05	GL
Genmab A/S : Q1 2025 Financial Results Presentation	08/05	PU
Genmab A/S : Interim Report for the First Quarter of 2025	08/05	PU
Genmab Announces Financial Results for the First Quarter of 2024	08/05	GL
Genmab Announces Financial Results for the First Quarter of 2024	08/05	AQ
Transactions in Connection with Share Buy-back Program	05/05	GL
Genmab to Submit Supplemental Biologics License Application to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide in Patients with Relapsed, Refractory Follicular Lymphoma	02/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : Beaten up share price offers an opportunity

June 06, 2025 at 06:10 pm IST

Genmab: From now on, courage to the most patient

April 01, 2025 at 08:27 pm IST